Navigation Links
Valensa Expands Astaxanthin Extraction Capacity

Growing Demand for High-Quality Finished Product that Meets Regulatory & Health Issues and New Strategic Alliance Create Conditions for Expansion

ORLANDO, Fla., Feb. 14 /PRNewswire/ -- Valensa International announced today that it has increased its capacity for the extraction of Haematococcus pluvialis for the manufacture of finished all-natural astaxanthin. The move was made in light of recently growing demand for a high-quality astaxanthin in North America, Asia and Europe that is both pesticide-free and allergen-free - two conditions that are only possible with select raw material sources and extraction facilities. In addition to market demand, a recently formed Strategic Alliance with Cyanotech Corporation (Kona, HI), where Valensa provides extraction services of raw material provided by Cyanotech, will require increased capacity to facilitate orderly growth of supply for the market and increased uptake of Valensa's own ZANTHIN(R) natural astaxanthin brand. The capacity expansion will be approximately 20% and will be achieved primarily through manufacturing efficiencies and de-bottlenecking its facilities in Eustis, Florida, USA. The expansion will include new facilities for screening biomass against the presence of pesticides. Astaxanthin products extracted at Valensa's Eustis facility will be certified pesticide- and allergen-free.

According to Dr. Rudi Moerck, President of Valensa, high-quality astaxanthin biomass and strict quality control in manufacturing are the two key elements for creating a finished astaxanthin product that meets or exceeds the quality and regulatory requirements of world markets. "There is growing interest and excitement about the potential of astaxanthin - the world's most potent antioxidant with clinical trial data indicating support in areas such as eye health, neurological health, immune support, inflammation reduction and skin health. Recently, the demand for a high-quality, pesticide-free source of the product has outstripped supply. The Strategic Alliance that we have formed with Cyanotech Corporation and our move to increase extraction capacity will help meet market requirements for this growing demand," he said. "Valensa has provided extraction services to Cyanotech for some time now and we were impressed by their biomass purity and pesticide-free profile," he said. "Our company has previously qualified a number of astaxanthin biomass sources, but product purity and overall product integrity led us to choose Cyanotech as our principal algae biomass supplier." Valensa's ZANTHIN(R) natural astaxanthin product has been marketed in the United States for over a decade and was the first astaxanthin extract to have Novel Foods approval in the European Union in July 2004. "These approvals require a pesticide-free, solvent-free and allergen-free astaxanthin. By qualifying our suppliers and screening our raw materials, through the use of supercritical carbon dioxide extraction technology and through our superior quality management, we are uniquely positioned to deliver the astaxanthin products required by world markets," said Dr. Moerck.

For further information, contact:

Dr. Rudi Moerck, President

Voice: 352-357-2004

Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit

SOURCE Valensa International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
2. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
3. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
4. PPD Expands Global Central Lab Services into China
5. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
6. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
7. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
8. Symmetry Medical Expands Board of Directors
9. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
10. Observant LLC Expands Senior Management Team
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
(Date:11/24/2015)... Muncie, IN (PRWEB) , ... November 24, 2015 , ... ... its newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to ... in the last few years. Many AMA members have embraced this type of racing ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... 2015 , ... Creation Technologies would like to extend our ... Technology Fast 500 list of the fastest growing companies in North America. , ... device that speeds up orthodontic tooth movement by as much as 50 percent. ...
Breaking Biology Technology:
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/23/2015)... California , October 23, 2015 ... (SMI) announce a mobile plug and play integration of ... real-world tasks SensoMotoric Instruments (SMI) present ... wearable solutions for eye tracking and physiological data registration. ... SMI Eye Tracking Glasses 2w and physiological ...
(Date:10/22/2015)... Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a leading ... first quarter ended September 30, 2015. --> ... fiscal 2016 grew 66 percent over the comparable quarter last year ... 2016 was $23.8 million, or $0.62 per diluted share. ... the first quarter of fiscal 2016 grew 39 percent over the ...
Breaking Biology News(10 mins):